Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Amicus Therapeutics (FOLD) over the last 7 years, with Q3 2025 value amounting to $310.4 million.

  • Amicus Therapeutics' Shares Outstanding (Diluted Average) rose 188.48% to $310.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.4 million, marking a year-over-year increase of 188.48%. This contributed to the annual value of $304.4 million for FY2024, which is 312.23% up from last year.
  • Amicus Therapeutics' Shares Outstanding (Diluted Average) amounted to $310.4 million in Q3 2025, which was up 188.48% from $308.3 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $310.4 million for Q3 2025, and its period low was $266.4 million during Q2 2021.
  • In the last 5 years, Amicus Therapeutics' Shares Outstanding (Diluted Average) had a median value of $295.8 million in 2023 and averaged $295.5 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 649.73% in 2022, and later soared by 98.97% in 2023.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Shares Outstanding (Diluted Average) stood at $271.4 million in 2021, then increased by 6.5% to $289.1 million in 2022, then increased by 2.11% to $295.2 million in 2023, then increased by 3.12% to $304.4 million in 2024, then increased by 1.99% to $310.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $310.4 million for Q3 2025, versus $308.3 million for Q2 2025 and $307.7 million for Q1 2025.